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A clinical trial is a success, not a failure, if it does not demonstrate efficacy or does identify safety
concerns
Dear editor,
As a group involved with the ethics review of clinical trials we en-
joyed the article by David Fogel describing the reasons why clinical
trials “fail” [1]. We firmly believe that along with protecting partici-
pants, an important role of Research Ethics Committees (RECs) is to
support researchers in carrying out high quality and successful research
[2].
In the UK the Health Research Authority (HRA) coordinates 66 RECs
that review around 700 clinical trials each year. Although REC review
occurs at the beginning of projects prior to participant recruitment,
HRA RECs have developed significant experience in reviewing proto-
cols and identifying issues, especially around experimental design, that
may contribute to future “trial failure”. However, from a REC per-
spective “trial failure” is approximately defined as the failure to com-
plete the research as described, and therefore failure to produce pub-
lished and relevant scientific or clinical knowledge.
Given this context we disagree strongly with David Fogel who de-
scribes the “primary reason for trial failure” as “failing to demonstrate
efficacy or safety”. While we can try to appreciate the perspective of a
pharmaceutical company whose aim is to develop a useable and mar-
ketable drug, intervention or technology, the entire basis for conducting
any form of trial must be a reasonable suspicion of clinical or safety
equipoise. Again we do appreciate that regulators insist on certain
studies being carried out prior to awarding a marketing authorisation,
but even these requested studies are based upon the regulator needing
the information on whether or not the proposed intervention (or dosage
regime) is at least safe. As a result, although unfortunate from the ex-
perimental team's point of view, demonstrating a lack of efficacy, or
uncovering previously unappreciated safety issues, represents a form of
trial success, not failure.
Our RECs also review trial amendments that are commonly pro-
duced as a result of trialists encountering unanticipated problems. We
therefore broadly concur with David Fogel on the other factors he lists
as leading to significant problems encountered by trialists. We also
broadly agree with his observation (under 4. Eligibility Criteria) that:
“Performing a requisite literature review for related studies remains a labour-
intensive task requiring personnel with specific knowledge who can interpret
the framework, criteria, and results of prior clinical trials.” BUT we do not
think this is a suitable excuse for poor study design and thus trial
failure. If trialists are unable or unwilling to complete a thorough lit-
erature review (and ideally referencing or conducting a systematic re-
view) prior to commencing a trial, they should not be conducting trials
in the first place. Time and again, through our RECs, we see studies
with inadequate scientific justifications and poorly designed meth-
odologies caused by incomplete engagement with the literature. Here
the answer is not artificial intelligence, it is better scholarship!
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.conctc.2018.10.004.
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